This page shows the latest oral anticoagulant news and features for those working in and with pharma, biotech and healthcare.
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved
These approvals mark the first generic approvals of a direct oral anticoagulant,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). ... Unlike older anticoagulants like warfarin, “direct oral
its innovative health unit and particularly Xeljanz – up 38% to $463m in the quarter – as well as breast cancer drug Ibrance (palbociclib) which rose 20% to $1bn and novel oral anticoagulant
Its pharma business was once again led by Bayer’s top-seller Xarelto, with sales of the oral anticoagulant rising 12.6% to 3.6bn, and eye drug Eylea, which was
Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa.
It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase
More from news
Approximately 0 fully matching, plus 78 partially matching documents found.
publication of the first direct oral anticoagulant technology appraisal, we are not yet there.
Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Delays and withdrawals. Eli Lilly was developing a once-daily, piperazine class, oral anticoagulant called LY 517717
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...